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databases was searched for eligible publications. The
following information was extracted from each study:
Name of first author, year of publication, country of
origin, sample size of cases and controls, and size of each
allele. The combined odds ratio (ORs) and 95% confi-
dence intervals (95%CIs) for the association between the
IL6 174 G/C gene polymorphism and the risk of oste-
oporosis were assessed using a random or fixed effects
model. A comprehensive meta-analysis (CMA) 2.0 was
used to analyse the data.
Results: Twelve studies (4923 cases/3431 controls) were
included in this meta-analysis. The results indicated that
IL6 174 G/C gene polymorphism was associated with
an increased (G vs C, OR 95%CI ¼ 1.29 [1.03e1.62],
p ¼ 0.029) and decreased risk of osteoporosis (C vs G,
OR 95%CI ¼ 0.77 [0.62e0.97], p ¼ 0.029; CC vs
GG þ GC, OR 95%CI ¼ 0.58 [0.39e0.88], p ¼ 0.010).
Conclusion: The IL6 174 G/C gene polymorphism was
shown to be positively correlated with osteoporosis risk.
Keywords: Genetic polymorphism; IL6 174 G/C gene
polymorphism; Osteoporosis
 2016 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Osteoporosis, an important public health problem, is a
very common multifactorial progressive skeletal orhis is an open access article under the CC BY-NC-ND license
16/j.jtumed.2016.07.010
nterleukin 6174 G/C gene polymorphism and the risk of osteoporosis:
oi.org/10.1016/j.jtumed.2016.07.010
J.K. Fajar and A. Azharuddin2metabolic bone disorder in the elderly that is characterized
by low bone density and microarchitectural deterioration of
bony tissue or bone mineral density (BMD) more than 2.5
SDs below the young normal mean.1e3 It results in loss of
bone mass, decreased bone strength,4 increased bone
fragility, and increased risk of developing spontaneous and
traumatic fractures.5,6 Osteoporosis is considered a silent
disease because it progresses without symptoms until a
fracture occurs.6 Osteoporosis affects 200 million
individuals worldwide,2 2.1 million females in England
and Wales,3 13 million in Japan,4 3.5 million in Italy,5 and
26 million in India.6 The frequency of osteoporosis varies
among studies. In the United States, the frequency of
osteoporosis was 4% of 50- to 59-year-old Caucasian
women and 52% of women aged 80 years or more,1 whereas
in India, the frequency of osteoporosis was 20% of women
and 10e15% of men.6 Osteoporosis is estimated to cause
1.5 million fractures annually in the United States,
including 300,000 hip fractures, approximately 700,000
vertebral fractures, 250,000 wrist fractures, and more
than 300,000 fractures at other sites.7 The mortality
associated with osteoporotic fractures ranges from 15 to
30%, a rate similar to that of breast cancer and stroke.5
The annual cost expenditure for osteoporotic fractures is
approximately £1.7 billion in England and Wales,1 £2100
million in England,3 over $14 billion in the United States
in 20031 and $16 billion in 2008,8 and it is predicted to
reach approximately $25.3 billion in 2025.9 Osteoporosis is
a common disease with a strong genetic component.10
Stewart and Ralston11 revealed that genetic factors play
an important role in regulating bone mineral density
and other determinants of osteoporotic fracture risk. IL6 is
one of the candidate genes that regulate bone density
because IL6 has some effect on the stimulation of
osteoclast resorption and has been implicated in the
pathogenesis of bone loss associated with oestrogen
deficiency.12
The IL6 gene is located at chromosome 7p21 and 5 in the
human genome. The gene contains four introns and five
exons.13 IL6 is a cytokine involved not only in inflamma-
tion and infection responses but also in the regulation
of metabolic, regenerative, and neural processes.14
Overexpression of IL6 has been implicated in the pathology
of a number of diseases, including osteoporosis.13 Several
studies have reported the role of IL6 in the pathogenesis of
osteoporosis. Bellido et al.15 revealed that IL6 mediates the
upregulation of osteoclastogenesis. Kudo et al.16 reported
that IL6, which is thought to play a role in several
osteolytic bone disorders, is directly capable of inducing
osteoclast formation by a receptor activator of nuclear
factor-kappa B ligand (RANKL)-independent mechanism.
Yoshitake et al.17 reported that IL6 directly acts on
osteoclast progenitors and suppresses their differentiation
by regulating the transcription of specific genes related to
mitogen-activated protein kinase (MAPK) phosphatases
and the ubiquitin pathway. Scheidt-Nave et al.18 found that
serum IL6 was elevated in postmenopausal osteoporosis.
Gaber et al.19 showed that the G/C promoter
polymorphism at 174 of the IL6 gene had an effect on
basal IL6 levels, and the C allele of the IL6 174 G/C gene
was associated with reduced gene expression and reduced
plasma levels of IL6.Please cite this article in press as: Fajar JK, Azharuddin A, The association betwe
A meta-analysis, Journal of Taibah University Medical Sciences (2016), http://Several polymorphism studies regarding the association
between the IL6 174 G/C gene polymorphism and the risk
of osteoporosis have shown inconsistent results. The studies
conducted by Magana et al.,20 Mendez et al.,21 and Ferrari
et al.22 showed that the IL6 174 G/C gene polymorphism
was associated with an increased risk of osteoporosis. In
contrast, the studies conducted by Czerny et al.,23 Garnero
et al.,24 Deveci et al.,25 Maedebbib26,26 Nordstrom et al.,27
Lee et al.,28 Korvala et al.,29 Dincel et al.,30 and Moffet
et al.31 showed that the IL6 174 G/C gene polymorphism
had no significant association with an increased risk of
osteoporosis. A meta-analysis study is the solution to
determine the actual association in the many studies.
This study aimed to investigate the association between
the IL6 174 G/C gene polymorphism and the risk of oste-
oporosis by performing a meta-analysis. The results of this
study are expected to be useful for the future treatment and
prevention of osteoporosis. In addition, this study is ex-
pected to be useful as a comparison to other studies of the
IL6 174 G/C gene polymorphism and osteoporosis.Materials and Methods
Study design
A meta-analysis was conducted to assess the association
between the IL6 174 G/C gene polymorphism and the risk
of osteoporosis. To achieve this goal, several studies
regarding this association were collected to calculate a
combined OR 95%CI, and the data were assessed using a
fixed or random effects model. An article search was con-
ducted in PubMed and Embase. The study was conducted
from January to April 2016.Study procedures
The procedures of this study were to (1) identify the
potentially relevant studies in PubMed and Embase up to
March 20th, 2016; (2) determine the eligibility of each study
using an exclusion process involving the following several
steps: (a) reading the title and abstract, (b) ensuring that the
study design complied with the inclusion criteria, and (c)
ensuring that the study provided sufficient data to calculate
OR 95%CI; (3) collect the abstract and full-text data from
the studies; (4) collect the data for calculating OR 95%CI;
and (5) analyse the data statistically.Eligibility criteria and data extraction
The eligibility criteria consisted of predefined inclusion
and exclusion criteria. Studies were included in the analysis if
they met the following inclusion criteria: (1) case-control; (2)
cohort; (3) cross-sectional studies; (4) randomized-controlled
trials (RCTs); (5) controlled before-and-after studies; (6)
cross-over studies; (7) evaluation of the association between
the IL6 174 G/C gene polymorphism and the risk of oste-
oporosis; and (8) sufficient data for calculation of OR 95%
CI. Some of the required data were extracted from each study
for calculating OR 95%CI. The following information was
extracted from each study: (1) name of first author; (2) yearen interleukin 6174 G/C gene polymorphism and the risk of osteoporosis:
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and controls; and (5) size of each allele.
Search strategy and literature
PubMed and Embase were searched with no language
restrictions using specified search terms to identify studies
published up to March 20th, 2016. The search strategy
involved the use of a combination of the following key words:
(IL 6 174 G/C gene) and (variant or variation or poly-
morphism) and (osteoporosis). The publication languages
were restricted to English. The reference lists of retrieved
articles were hand-searched. If more than one article was
published using the same study data, only the study with the
largest sample size was included. We used a scoring system to
evaluate the quality of the studies. We used a quality
assessment score modified from previous meta-analysis for
observational studies. The total scores ranged from 0 (worst)
to 9 (best). A study was considered low quality if the score
was <6 and high quality if the score was 6.32
Study variables
1. Interleukin 6 174 G/C
Interleukin-6 is a cytokine involved not only in inflam-
mation and infection responses but also in the regulation of
metabolic, regenerative, and neural processes.14 The
measurement results of this variable were the G and C
alleles. Data were obtained by a search strategy. A nominal
scale was used to assess this variable.
2. Risk of osteoporosis
Osteoporosis is a very common multifactorial progressive
skeletal or metabolic bone disorder in the elderly that is
characterized by low bone density and microarchitectural
deterioration of bony tissue or a bone mineral density
(BMD)more than 2.5 SDs below the young normal mean.1e3
The measurement results of this variable were an increased or
decreased risk of osteoporosis. The data were obtained by a
search strategy. A nominal scale was used to assess this
variable.
Statistical analysis
The correlation between the IL6 174 G/C gene poly-
morphism and the risk of osteoporosis was estimated by
calculating pooled ORs and 95%CIs. The significance of
pooled ORs was determined by Z tests (p < 0.05 was
considered statistically significant). A Q test was performed
to evaluate whether heterogeneity existed. A random effects
model was used to calculate OR 95%CI if heterogeneity
existed (p < 0.10). A fixed effect model was used to calculate
OR 95%CI if no heterogeneity existed. Publication bias was
assessed by Egger’s test (p < 0.05 was considered statistically
significant). Subgroup analyses based on continent (Europe,
America, and Asia), gender (female, male, and mixed), and
sample size (small < 400, large  400 samples) were also
performed. A comprehensive meta-analysis (CMA) 2.0 was
used to analyse the data.Please cite this article in press as: Fajar JK, Azharuddin A, The association betwe
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Characteristics of the studies
A total of 1798 potentially relevant papers were identified
based on the search strategy. Of these, 1769 papers were
excluded because of obvious irrelevance by reading their ti-
tles and abstracts. After the full texts were read, six papers
were excluded because they did not provide sufficient data
for calculation of OR with 95%CI; two papers were excluded
because they were family-based studies. In addition, nine
reviews were excluded. A flow chart demonstrating the in-
clusion or exclusion of studies is displayed in Figure 1. A
total of 12 studies were included in the meta-analysis.
Seven studies were from Europe, four studies were from
America, and one study was from Asia. Table 1 describes the
characteristics of the studies included in the meta-analysis.Quantitative data synthesis
A total of 4923 cases and 3431 controls were identified.
Overall, the results showed that allele G vs C, C vs G, and CC
vs GG þ GC had significant associations with the risk of
osteoporosis. In contrast, GG vs GC þ CC and GC vs
GGþ CCGC had no significant associations with the risk of
osteoporosis. The results indicated that the IL6 174 G/C
gene polymorphism was associated with an increased (G vs
C, OR 95%CI¼ 1.29 [1.03e1.62], p¼ 0.029) and a decreased
risk of osteoporosis (C vs G, OR 95%CI ¼ 0.77 [0.62e0.97],
p ¼ 0.029; CC vs GG þGC, OR 95%CI ¼ 0.58 [0.39e0.88],
p¼ 0.010). A forest plot showing the correlation between the
IL6 174 G/C gene polymorphism and the risk of osteopo-
rosis is shown in Figure 2 for G vs C. A summary of ORs and
95%CIs regarding the correlation between the IL6 174 G/
C gene polymorphism and the risk of osteoporosis is
described in Table 2. In the subgroup analysis, the IL6
174 G/C gene polymorphism was associated with the risk
of osteoporosis in two genetic models of the European
continent subgroup (GC vs GG þ CC p ¼ 0.005; CC vs
GG þ GC p ¼ 0.017), two genetic models of the American
continent subgroup (G vs C p ¼ 0.019; C vs G p ¼ 0.019),
three genetic models of the female subgroup (G vs C
p ¼ 0.047; C vs G p ¼ 0.047; CC vs GG þ GC p ¼ 0.028),
four genetic models of the mixed gender subgroup (G vs C
p ¼ 0.007; GG vs GC þ CC p ¼ 0.024; GC vs GG þ CC
p < 0.001; C vs G p ¼ 0.007), and one genetic model of the
small-sample-size subgroup (CC vs GG þGC p ¼ 0.024). In
contrast, the IL6 174 G/C gene polymorphism had no
significant association with the risk of osteoporosis in three
genetic models of the European continent subgroup (G vs C
p ¼ 0.497; GG vs GC þ CC p ¼ 0.333; C vs G p ¼ 0.497),
three genetic models of the American continent subgroup
(GG vs GCþC p¼ 0.100; GC vs GGþCC p¼ 0.433; CC vs
GG þ GC p ¼ 0.054), all genetic models of the Asia conti-
nent subgroup (G vs C p ¼ 0.723; GG vs GC þ CC
p¼ 0.722; GC vs GG þ CC p¼ 0.722; C vs G p ¼ 0.723; CC
vs GG þ GC p ¼ NA), two genetic models of the female
subgroup (GG vs GC þ CC p ¼ 0.163; GC vs GG þ CC
p ¼ 0.535), all genetic models of the male subgroup (G vs C
p ¼ 0.635; GG vs GC þ CC p ¼ 0.205; GC vs GG þ CC
p¼ 0.118; C vs G p¼ 0.635; CC vs GGþGC p¼ 0.595), oneen interleukin 6174 G/C gene polymorphism and the risk of osteoporosis:
dx.doi.org/10.1016/j.jtumed.2016.07.010
Table 1: Characteristics of studies included in the meta-analysis.
Author & Year Country Continent Mean age SD Gender SS NS Ost genotype Cont genotype
Ost Cont GG GC CC GG GC CC
Czerny et al., 2010 Poland Europe 63.3  5.1 Female L 226 224 67 126 33 76 103 45
Magana et al., 2008 Mexico America 34.3  10.2 Female S 70 70 56 13 1 42 25 3
Garnero et al., 2002 France Europe 64.6  8.8 Female L 372 255 134 180 58 93 126 36
Deveci et al., 2012 Turkey Europe 57.0  7.0 Female S 201 155 127 50 24 93 31 31
Mendez et al., 2013 Mexico America 58.3  6.8 Female S 180 180 138 37 5 53 95 32
Maedeb 2009 France Europe 70.0  7.4 Female S 92 69 34 47 11 30 30 9
Nordstrom et al., 2004 Sweden Europe 75.0  0.0 Female L 232 544 68 121 43 167 246 131
Lee et al., 2010 South Korea Asia 12.5  1.4 Female S 198 120 197 1 0 119 1 0
Korvala et al., 2010 Finland Europe 20.3  1.6 Male S 72 120 15 42 15 35 56 29
Dincel et al., 2008 Turkey Europe 74.5  8.9 Mixed S 20 17 0 10 10 0 7 10
Ferrari et al., 2004 USA America 60.1  9.5 Mixed L 626 935 206 390 30 360 390 185
Moffett et al., 2004 USA America 73.0  5.0 Female L 2634 742 869 1272 493 245 354 143
Notes USA¼United States of America, SD ¼ standard deviation, SS ¼ sample size, L ¼ large (400 samples), S ¼ small (<400 samples),
NS ¼ number of samples, Ost ¼ osteoporosis, cont ¼ control.
Figure 2: Meta-analysis of the association between the IL6 174 G/C gene polymorphism and the risk of osteoporosis (G vs C).
Figure 1: Selection of articles for inclusion in the meta-analysis.
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Table 2: Summary of ORs and 95%CIs in the association between the IL6L174 G/C gene polymorphism and the risk of osteoporosis.
No. Genetic model Parameter All Continent Gender Sample size
Europe America Asia Female Male Mixed S L
1 G vs C OR 1.29 1.04 1.90 1.65 1.37 0.90 1.22 1.62 1.07
95%CI 1.03e1.62 0.93e1.17 1.11e3.23 0.10e26.54 1.00e1.87 0.60e1.37 1.05e1.41 0.87e3.03 1.00e1.15
p 0.029 0.497 0.019 0.723 0.047 0.635 0.007 0.129 0.094
pH <0.001 0.711 <0.001 1.000 <0.001 1.000 <0.001 <0.001 0.296
pE 0.337 <0.001 0.511 <0.001 0.415 <0.001 <0.001 0.741 0.044
2 GG vs GC þ CC OR 1.20 0.92 1.93 1.65 1.36 0.64 0.78 1.65 0.91
95%CI 0.84e1.70 0.77e1.09 0.88e4.24 0.10e26.71 0.88e2.10 0.32e1.28 0.63e0.97 0.65e4.18 0.81e1.02
p 0.313 0.333 0.100 0.722 0.163 0.205 0.024 0.291 0.102
pH <0.001 0.722 <0.001 1.000 <0.001 1.000 1.000 <0.001 0.478
pE 0.517 <0.001 0.768 <0.001 0.588 <0.001 <0.001 1.056 <0.001
3 GC vs GG þ CC OR 1.06 1.26 0.72 1.60 0.89 1.60 2.28 0.82 1.35
95%CI 0.74e1.50 1.07e1.49 0.37e1.64 0.04e9.75 0.63e1.27 0.89e1.89 1.86e2.80 0.40e1.69 0.94e1.95
p 0.762 0.005 0.433 0.722 0.535 0.118 <0.001 0.591 0.108
pH <0.001 0.627 <0.001 1.000 <0.001 1.000 0.476 <0.001 <0.001
pE 0.534 <0.001 0.808 <0.001 0.456 <0.001 <0.001 0.855 0.392
4 C vs G OR 0.77 0.96 0.53 0.60 0.73 1.10 0.82 0.62 0.94
95%CI 0.62e0.97 0.86e1.08 0.31e1.90 0.04e9.72 0.53e0.10 0.73e1.67 0.70e0.95 0.33e1.15 0.87e1.01
p 0.029 0.497 0.019 0.723 0.047 0.635 0.007 0.129 0.094
pH <0.001 0.711 <0.001 1.000 <0.001 1.000 0.926 <0.001 0.296
pE 0.337 <0.001 0.511 <0.001 0.415 <0.001 <0.001 0.741 0.044
5 CC vs GG þ GC OR 0.58 0.77 0.31 NA 0.69 0.83 0.32 0.51 0.64
95%CI 0.39e0.88 0.63e0.95 0.09e1.02 NA 0.49e0.96 0.41e1.67 0.10e1.03 0.29e0.92 0.36e1.14
p 0.010 0.017 0.054 NA 0.028 0.595 0.056 0.024 0.131
pH <0.001 0.589 <0.001 NA 0.003 1.000 0.077 0.051 <0.001
pE 0.584 <0.001 1.087 NA 0.355 <0.001 0.719 0.512 0.622
Notes OR ¼ odds ratio, CI ¼ confidence interval, p ¼ p value based on a between-study Z test, pH ¼ p value based on Q test for het-
erogeneity between studies, pE ¼ p value based on Egger’s test between studies, NA ¼ not available, L ¼ large (400 samples), S ¼ small
(<400 samples).
The association between interleukin 6 174 G/C and the risk of osteoporosis 5genetic model of the mixed gender subgroup (CC vs
GG þ GC p ¼ 0.056), four genetic models of the small-
sample-size subgroup (G vs C p ¼ 0.129; GG vs GC þ CC
p ¼ 0.291; GC vs GG þ CC p ¼ 0.591; C vs G p ¼ 0.129),
and all genetic models of the large-sample-size subgroup
(G vs C p ¼ 0.094; GG vs GC þ CC p ¼ 0.102; GC vs
GG þ CC p ¼ 0.108; C vs G p ¼ 0.094; CC vs GG þ GC
p ¼ 0.131).
Source of heterogeneity
Evidence for heterogeneity (p< 0.10) between studies was
found in all multiplicative models (G vs C pH< 0.001; GG vs
GC þ CC pH < 0.001; GC vs GG þ CC pH < 0.001; C vs G
pH < 0.001; CC vs GG þ GC pH < 0.001). Therefore, the
data in this study were assessed using a random effects
model. A summary of the evidence of heterogeneity
regarding the correlation between the IL6 174 G/C gene
polymorphism and the risk of osteoporosis is described in
Table 2. In the subgroup analysis, evidence for heterogeneity
was found in the American continent subgroup, female
subgroup, mixed gender subgroup, small-sample-size sub-
group, and large-sample-size subgroup. Therefore, a random
effects model was used to calculate OR 95%CI in these
subgroups. In contrast, no evidence of heterogeneity was
found in the European continent subgroup, Asian continent
subgroup, male subgroup, mixed gender subgroup, and
large-sample-size subgroup. Therefore, a fixed effect model
was used to calculate OR 95%CI in these subgroups.Please cite this article in press as: Fajar JK, Azharuddin A, The association betwe
A meta-analysis, Journal of Taibah University Medical Sciences (2016), http://Potential publication bias
Using Egger’s test, no publication bias could be detected
(G vs C pE ¼ 0.337; GG vs GC þ CC pE ¼ 0.517; GC vs
GG þ CC pE ¼ 0.534; C vs G pE ¼ 0.337; CC vs GG þ GC
pE ¼ 0.584). A summary of Egger’s test regarding the cor-
relation between the IL6 174 G/C gene polymorphism and
the risk of osteoporosis is described in Table 2. In the
subgroup analysis, no publication bias was detected in the
American continent subgroup (G vs C pE ¼ 0.511; GG vs
GC þ CC pE ¼ 0.768; GC vs GG þ CC pE ¼ 0.808; C vs
G pE ¼ 0.511; CC vs GG þ GC pE ¼ 1.087), female
subgroup (G vs C pE ¼ 0.415; GG vs GC þ CC
pE ¼ 0.588; GC vs GG þ CC pE ¼ 0.456; C vs G
pE ¼ 0.415; CC vs GG þ GC pE ¼ 0.355), mixed gender
subgroup (CC vs GG þ GC pE ¼ 0.719), small-sample-size
subgroup (G vs C pE ¼ 0.741; GG vs GC þ CC
pE ¼ 1.056; GC vs GG þ CC pE ¼ 0.855; C vs G pE ¼ 0.741;
CC vs GG þ GC pE ¼ 0.512), and large-sample-size sub-
group (GC vs GG þ CC pE ¼ 0.392; CC vs GG þ GC
pE ¼ 0.622). In contrast, publication bias was detected in the
European continent subgroup (G vs C pE < 0.001; GG vs
GC þ C pE < 0.001; GC vs GG þ CC pE < 0.001; C vs G
pE < 0.001; CC vs GG þ GC pE < 0.001), Asian continent
subgroup (G vs C pE< 0.001; GG vs GCþC pE< 0.001; GC
vs GG þ CC pE < 0.001; C vs G pE < 0.001), male subgroup
(G vs C pE < 0.001; GG vs GC þ C pE < 0.001; GC vs
GG þ CC pE < 0.001; C vs G pE < 0.001; CC vs GG þ GC
pE< 0.001), mixed gender subgroup (G vs C pE< 0.001; GGen interleukin 6174 G/C gene polymorphism and the risk of osteoporosis:
dx.doi.org/10.1016/j.jtumed.2016.07.010
J.K. Fajar and A. Azharuddin6vs GC þ C pE < 0.001; GC vs GG þ CC pE < 0.001; C vs G
pE < 0.001), and large-sample-size subgroup (G vs C
pE ¼ 0.044; C vs G pE ¼ 0.044).Discussion
IL6 is a cytokine involved not only in inflammation and
infection responses but also in the regulation of metabolic,
regenerative, and neural processes.14 Overexpression of IL6
has been implicated in the pathology of a number of
diseases including osteoporosis.13 Several studies have
reported the role of IL6 in the pathogenesis of
osteoporosis. Scheidt-Nave et al.18 found that serum IL6
was elevated in postmenopausal osteoporosis. Gaber
et al.19 showed that G/C promoter polymorphism at 174
of the IL-6 gene affected basal IL6 levels, and the C allele
of the IL6 174 G/C gene was associated with reduced gene
expression and reduced plasma levels of IL6. Because of the
effects of IL6 on the inflammatory response, a series of
studies have focused on the contribution of polymorphisms
within IL6 cluster genes to the osteoporosis risk. However,
the results have been contradictory. This study reported the
association between the IL6 174 G/C gene polymorphism
and the risk of osteoporosis, although the meta-analysis was
limited due to the size and heterogeneity of the studies.
The results indicated that the IL6 174 G/C gene poly-
morphism was associated with an increased (G vs C, OR
95%CI ¼ 1.29 [1.03e1.62], p ¼ 0.029) and decreased risk of
osteoporosis (C vs G, OR 95%CI ¼ 0.77 [0.62e0.97],
p ¼ 0.029; CC vs GG þGC, OR 95%CI ¼ 0.58 [0.39e0.88],
p ¼ 0.010). A summary of the ORs 95%CIs, correlation,
heterogeneity, and Egger’s test regarding the correlation
between the IL6 174 G/C gene polymorphism and the risk
of osteoporosis is described in Table 2, and the study
characteristics are described in Table 1. A forest plot
showing the correlation between the IL6 174 G/C gene
polymorphism and the risk of osteoporosis is described in
Figure 2 for G vs C. Previous similar meta-analyses have
reported the correlation between IL6 gene polymorphism
and the risk of osteoporosis and fracture. Wang et al.33
studied the association between the IL6 634 C/G
and 174 G/C polymorphisms with bone mineral density
(BMD). They showed that the 634 C/G and 174 G/C
polymorphisms had modest effects on BMD. However,
they did not include an analysis of each genetic model and
did not focus on the risk of osteoporosis; they only
correlated the polymorphisms to BMD score. Our study
only focused on the risk of osteoporosis and provided the
results of an analysis of several genetic models. Therefore,
these results are expected to be complementary to several
gene studies regarding the risk of osteoporosis. Another
study by Wang et al.34 evaluated the association between
the IL6 174 G/C gene polymorphism and the risk of
fracture. They showed that the IL6 174 C/G gene
polymorphism was associated with an increased risk of
wrist and osteoporotic fracture (OR 95%CI ¼ 1.60 [1.12e
2.28]). A study by Zhang et al.35 analysed the association
between IL6 174 G/C and fracture risk. They found that
the IL6 174 G/C polymorphism contributed to the
development of fracture (OR 95%CI ¼ 1.32 [1.10e1.58]).
However, the study characteristics were not included, andPlease cite this article in press as: Fajar JK, Azharuddin A, The association betwe
A meta-analysis, Journal of Taibah University Medical Sciences (2016), http://only six studies were included in the Wang et al.34 and
Zhang et al.35 studies. Thus, a larger sample size was
needed to determine a better association. Our study used a
larger sample size. Therefore, the results of our study are
expected to provide superior results. Furthermore, in the
subgroup analysis, the IL6 174 G/C gene polymorphism
was associated with the risk of osteoporosis in two genetic
models of the European continent subgroup (GC vs
GG þ CC; CC vs GG þ GC), two genetic models of the
American continent subgroup (G vs C; C vs G), three
genetic models of the female subgroup (G vs C; C vs G;
CC vs GG þ GC), four genetic models of the mixed
gender subgroup (G vs C; GG vs GC þ CC; GC vs
GG þ CC; C vs G), and one genetic model of the small-
sample-size subgroup (CC vs GG þ GC). In contrast, the
IL6 174 G/C gene polymorphism had no significant asso-
ciation with the risk of osteoporosis in three genetic models
of the European continent subgroup (G vs C; GG vs
GC þ CC; C vs G), three genetic models of the American
continent subgroup (GG vs GC þ C; GC vs GG þ CC; CC
vs GG þ GC), all genetic models of the Asian continent
subgroup, two genetic models of the female subgroup (GG vs
GC þ CC; GC vs GG þ CC), all genetic models of the male
subgroup, one genetic model of the mixed gender subgroup
(CC vs GG þ GC), four genetic model of the small-sample-
size subgroup (G vs C; GG vs GCþCC; GC vs GGþCC; C
vs G), and all genetic models of the large-sample-size sub-
group. However, these results should be interpreted with
caution considering that the relatively small sample size or
multiple testing could have resulted in false-positive findings.
These results also indicated that the G allele of the
IL6 174 G/C gene was correlated with susceptibility to
osteoporosis, whereas the C allele was correlated with a
reduced risk of osteoporosis. See Table 2 for a detailed
summary of the ORs 95%CIs regarding the correlation
between the IL6 174 G/C gene polymorphism and the risk
of osteoporosis. Theoretically, these results are clearly
unexplainable. However, several studies have supported
these results. Scheidt-Nave et al.18 conducted a study
regarding the role of serum IL6 as a predictor of bone loss
in 137 postmenopausal German women. They found that
serum IL6 was a predictor of postmenopausal bone loss and
that the effect appears to be most relevant through the first
postmenopausal decade. A study by Ershler and Keller36
revealed that after menopause, IL6 levels are elevated, even
in the absence of infection, trauma, or stress, and this
condition was associated with low BMD levels. Li et al.37
conducted a study regarding the contribution of IL6 to the
osteogenesis of osteoporotic mice. They showed that IL6
over-secretion impaired osteogenesis in osteoporotic mice.
They also showed that in vivo administration of IL6
neutralizing antibody was helpful to rescue the osteoporotic
phenotype in the mouse vertebral body. De Benedetti et al.38
conducted a study regarding in vivo neutralization of IL6 by
human IL-6 (hIL-6) receptor antagonist in osteoporotic mice.
They found that immunization with hIL-6 receptor antago-
nist could represent a novel and simple therapeutic approach
for the specific neutralization of IL6. A study by Theoharides
et al.39 also found that serum IL6was elevated in osteoporosis
patients and was correlated with severity of symptoms. Based
on these studies, it can be concluded that serum IL6 levels
have a correlation with osteoporosis. Serum IL6 levels areen interleukin 6174 G/C gene polymorphism and the risk of osteoporosis:
dx.doi.org/10.1016/j.jtumed.2016.07.010
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has reported the association of serum IL levels with174G/C
promoter polymorphism in osteoporotic models. However,
several studies have reported this association in other
disease models. Gaber et al.19 conducted a study regarding
the correlation between serum IL6 and 174 G/C promoter
polymorphism in rheumatoid arthritis patients. They found
that the G allele of the IL6 174 gene had a significant
positive correlation with serum IL6 levels, whereas the C
allele had a significant negative correlation with serum IL6
levels. Belluco et al.40 conducted a study regarding the
association between serum IL6 levels and the 174 G/C
gene polymorphism in patients with colorectal cancer. They
found that C subjects produced higher IL6 levels than did
Cþ subjects. Tonet et al.41 conducted a study regarding the
correlation between serum IL6 levels and the 174 G/C
gene polymorphism in patients with cardiovascular disease.
They found that serum IL6 levels were markedly lower in
the C allele, whereas the G allele displayed a trend towards
higher levels of circulating IL6. Fishman et al.42 conducted
a study regarding the association between serum IL6 levels
and the 174 G/C gene polymorphism in patients with
systemic-onset juvenile chronic arthritis. They found that
the C allele was associated with significantly lower levels of
plasma IL6. Burzotta et al.43 conducted a study regarding the
association between serum IL6 levels and the174 G/C gene
polymorphism in patients with cardiovascular disease. They
showed that the G allele was associated with higher levels of
serum IL6. Therefore, the results of this study showing that
the G allele of the IL6 174 G/C gene polymorphism
correlated with a susceptibility to osteoporosis are
understandable because the G allele of the IL6 174 G/C
gene polymorphism has an association with increased levels
of serum IL6.
Osteoporosis is a very common multifactorial progressive
skeletal or metabolic bone disorder in the elderly character-
ized by low bone density and microarchitectural deteriora-
tion of bony tissue or BMD more than 2.5 SDs below the
young normal mean.1e3 The role of IL6 in the osteoporosis
process is complex. The balance between bone resorption
caused by osteoclasts and bone formation caused by
osteoblasts plays an important role in bone metabolism.
The lower serum oestrogen levels in postmenopausal
women cause an imbalance between osteoblasts and
osteoclasts.44 IL6, a multifunctional cytokine involved in
osteoclast differentiation, is secreted by osteoblasts and
appears to be a key molecule in the osteoporotic process.45
The expression of the IL6 gene in osteoblasts and bone
marrow stromal cells is down-regulated by oestrogen.44 IL6
is widely recognized as a potent stimulator of osteoclast-
driven bone absorption in the context of chronic inflamma-
tion and oestrogen deficiency.46 The mechanism of IL6 in the
process of osteoporosis is twofold, occurring both inside and
outside the osteoclast cells. In osteoclast cells, IL6 has an
important role in bone resorption by activating immature
osteoclasts. Under normal conditions, oestrogen inhibits
the IL6 promoter in the absence of a functional oestrogen
receptor (ER) binding site. This process is mediated by
nuclear factor e kappa B (NF-kB) and CCAAT-enhancer-
binding proteins (C/EBP) b.44 The ER impairs IL6
induction by preventing c-rel and, to a lesser extent, RelA
proteins from binding to the NF-kB site of the IL6Please cite this article in press as: Fajar JK, Azharuddin A, The association betwe
A meta-analysis, Journal of Taibah University Medical Sciences (2016), http://promoter.47 ER directly interacts with the nuclear factor
interleukin-6 (NF-IL6) and NF-kB and inhibits their abil-
ity to bind deoxyribonucleic acid (DNA), which might be the
molecular basis for repression of IL6 gene expression by
oestrogens.48 The physical and functional interaction
depends on the DNA binding domain and region D of the
ER and on the Rel homology domain of NF-kB and the
basic leucine zipper (bZIP) region of C/EBP b. The cross-
coupling among ER, NF-kB, and C/EBP b also results in
reduced activity of promoters with the ER binding sites.44
This leads to a balance between osteoblast and osteoclast
activity. However, in pathological states or oestrogen
deficiency, IL6 acts to activate immature osteoclasts
without restriction, mediated by NF-kB, C/EBP b, and nu-
clear factors of activated T-cells cytoplasmic 1 (NFATc1).44
This leads to an imbalance between osteoblast and osteoclast
activity, where osteoclast activity is more dominant than
osteoblast activity, causing bone loss and osteoporosis.
Outside osteoclast cells, after release from osteoblast-
lineage cells,49 IL6 first binds to IL6R and forms a
complex with gp130 to stimulate intracellular signalling
machinery. IL6 then stimulates osteoblastic downstream
production of signalling molecules, especially RANKL,
which subsequently enhances osteoclast formation and
activity.46 IL6 induces the expression of RANKL on the
surface of osteoblasts. RANKL then interacts with
receptor activator of nuclear factor e kappa B (RANK)
expressed on osteoclast progenitors, inducing osteoclast
differentiation via the RANK signalling pathway, which
involves NF-kB, c-Jun N-terminal kinase (JNK), and p38.
IL6 also directly acts on osteoclast progenitors to suppress
their differentiation via an inhibition of RANK signalling
pathways. IL6 specifically suppresses RANK-mediated I
kappa B (IkB) degradation and JNK activation. IL6 and
RANKL up-regulate the transcription of MKP1 andMKP7,
which encode enzymes that dephosphorylate JNK, and
down-regulate the transcription of sentrin-specific protease 2
(Senp2) and cullin 4A (Cul4A), which are related to the
ubiquitin pathway.17 Furthermore, the activity of IL6 on
osteoclasts frequently interplays with IL1 and tumour
necrosis factor (TNF), and IL6 increases the stimulatory
effect of IL1 and TNF on bone resorption by increasing
the osteoclastic progenitor pool.46 These mechanisms are
thought to underlie the results of this study that showed a
correlation between the IL6 174 G/C gene polymorphism
and the risk of osteoporosis.
There were several limitations to the meta-analysis. First,
our analysis was primarily based on unadjusted effect esti-
mates. Therefore, the potential covariates, including age,
gender, menopausal factors, history of trauma, and smoking
habits, were not controlled for. Second, the possibility of a
false negative exists due to the small size of the studies, even
when combined. Thus, further studies with larger sample
sizes are required to investigate the associations.Conclusions and suggestions
In summary, our meta-analysis suggested that the G allele
of the IL6 174 G/C gene polymorphism was associated
with an increased risk of osteoporosis, whereas the C allele of
the IL6 174 G/C gene polymorphism was associated with aen interleukin 6174 G/C gene polymorphism and the risk of osteoporosis:
dx.doi.org/10.1016/j.jtumed.2016.07.010
J.K. Fajar and A. Azharuddin8decreased risk of osteoporosis. Further studies considering
geneeenvironment interactions should be conducted to
investigate the associations between the IL6 174 G/C gene
polymorphism and the risk of osteoporosis.
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